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Abstract
Aim: The aims of the current study were to assess the validity of the fecal occult blood test (FOBT) in an organized screening
setting in Korea and to determine factors associated with FOBT validity, such as screening round, age group, and anatomical
location of the cancer.
Methods: Study participants were those who were 50 years and older who received an FOBT through the National Cancer
Screening Program between 2004 and 2007. Colorectal cancer diagnoses were ascertained through linkage with the Korean
National Cancer Incidence Database. The positivity rate, colorectal cancer detection rate, interval cancer rate, sensitivity,
specificity, and positive predictive value of the FOBT were calculated.
Results: A total of 2,193,093 tests were included in the analysis. Overall, the sensitivity of the FOBT for colorectal cancer was
59.7% for the first round and 56.1% for the subsequent round. Sensitivity was highest for distal colon cancer (65.9%) in the
first round, and for rectal cancer (58.4%) for the subsequent round. The sensitivity and positive predictive value of the FOBT
generally improved between 2004 and 2008.
Conclusions: The FOBT showed reasonable validity in an organized screening setting, and the validity of the FOBT varied by
screening round, anatomical location, and screening year.
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Introduction
Colorectal cancer (CRC) incidence and mortality has been
increasing in Korea. The age-standardized mortality rate for CRC
was 1.7 per 100,000 in 1983 and increased to 17.4 in 2010 in men
and increased from 1.6 in 1983 to 13.5 in 2010 in women [1]. A
joint regression analysis showed that mortality rates increased
7.7% annually between 1983 and 2002, then stabilized in men.
Similarly, mortality rates increased 9.1% annually between 1983
and 1994, and 4.2% between 1994 and 2004 then stabilized in
women [2]. Annual percent changes in age-standardized incidence
rates for CRC were 7% in men and 5.3% in women between 1999
and 2008 [3]. As a result, by 2009, CRC had become the second
most common cancer in men and the third most common cancer
in women [4].
The rapid increase in CRC incidence could be explained not
only by changes in risk factors, but also by the dissemination of
CRC screening. Based on evidence that screening reduces CRC
mortality [5–8], national guidelines in several countries now
recommend regular CRC screening for average-risk persons aged
50 years or older using one or more of the following options: an
annual fecal occult blood test (FOBT), flexible sigmoidoscopy
every 5 years, a combination of FOBT and flexible sigmoidoscopy,
colonoscopy every 10 years, and/or double-contrast barium
enema (DCBE) every 5 years [9]. Recently, the Asia Pacific
Working Group on CRC reached a consensus to develop
guidelines for CRC screening and recommended the FOBT,
flexible sigmoidoscopy, and colonoscopy as the best options [10].
In Korea, the government introduced nationwide CRC screening
as part of the National Cancer Screening Program (NCSP) for
Medical Aid recipients and National Health Insurance (NHI)
beneficiaries in the lower 50% income bracket in 2004. The NCSP
provides an annual FOBT free of charge as the primary screening
method for men and women aged 50 years or older. In FOBT-
positive individuals, the NCSP also provides follow-up investiga-
tion by either colonoscopy or DCBE [11].
In population-based, organized screening settings with cancer
case ascertainment by linkage to a cancer registry database, test
sensitivity for the latex agglutination FOBT was 73.8% in an
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Italian study [12]. Several factors have been associated with the
validity of the FOBT. The average FOBT hemoglobin content
among adenoma patients was higher for older age groups and
those with a left-side colon tumor after adjustment for the clinical
characteristics of adenoma [13]. In a systematic review of
prospective studies that were conducted among average-risk
adults, all of whom had an FOBT and colonoscopy, and that
reported site-specific FOBT sensitivity for advanced neoplasia, 5
out of 8 studies showed that the FOBT had higher sensitivity for
left-sided advanced neoplasia, although the confidence intervals
overlapped due to limited sample sizes [14].
The objective of the current study was to assess the validity of
the FOBT in the NCSP setting in Korea and to determine factors
associated with FOBT validity, such as screening round, screening
year, sex, age group, FOBT kit (qualitative/quantitative), and
anatomical location of the cancer.
Materials and Methods
Study population
Data were obtained from the NCSP database, which contains
information on Medical Aid recipients and on the NHI
beneficiaries invited to participate in the NCSP. The NCSP
provides an annual CRC screening through a fecal immuno-
chemical test (FIT; qualitative or quantitative) for men and women
aged 50 years and older. Within the framework of the NCSP,
eligible men and women receive an invitation letter from the NHI
Corporation (NHIC) at the beginning of each calendar year. In
2004, Medical Aid recipients and NHI beneficiaries in the lower
30% income bracket were eligible for the program. In 2005, the
NCSP expanded its target population to the lower 50% income
bracket. All of the target population receives an invitation letter
from the NHIC at the beginning of the year.
In the colorectal cancer screening Program, FOBT was
performed as a primary screening test by using one-day fecal
immunochemical test instead of guaiac FOBT. FIT tests use
specific antibodies against human blood components. For immu-
nochemical FOBT, stool samples were collected by the individuals
themselves either at home or at a screening center. In the
laboratory, immunochemical FOBT is performed either qualita-
tive (positive/negative) or quantitative (measurement of fecal
hemoglobin content) method. Qualitative immunochemical
FOBTs use immunochromatographic technology, and it allows
simple and office-based analysis. Quantitative immunochemical
FOBTs have important advantages over qualitative FOBTs in
terms of their automation, which removes interobserver variation
in the interpretation of test results, improving reproducibility and
allowing for high-throughput testing. Four commercially available
qualitative immunochemical FOBT kits (OC-Hemocatch Lignt
TM, Eiken Chemical Co., Japan, cut-off point of 50 ng/ml; FOB
test, Humasis Co., Korea, cut-off point of 50 ng/ml; SD Bioline
FOB, SD Co., Korea, cut-off point of 30 ng/ml; ASAN Easy Test
FOB, Asan Pharm Co., Korea, cut-off point of 50 ng/ml) are
widely used in Korea. Regarding quantitative immunochemical
FOBT, OC sensor method by latex agglutination nephelometric
immunoassay (Eiken Chemical Co. Japan) is most popularly used.
Each colorectal cancer screening unit chose which method to be
used in their unit. In 2009, 72.8% of participants received a
qualitative FIT and 27.2% received a quantitative FIT through
NCSP for colorectal cancer.
Participants were notified of the FOBT results (reported as
‘positive’ or ‘negative’). Participants who had a positive FOBT
result were contacted by telephone by the medical staff, informed
of the positive test result, and offered an appointment date for
follow-up testing by either colonoscopy or DCBE free of charge.
FOBT-positive participants could choose their preferred follow-up
test. All of these examinations were performed free of charge at a
clinic or hospital designated as a CRC screening unit by the
NHIC. To be designated as a CRC screening unit, a clinic or
hospital must have colonoscopy equipment and at least one full-
time medical doctor. CRC screening units must be able to conduct
not only FOBT testing but also follow-up colonoscopy.
The population for the current study was restricted to men and
women aged 50 years or older who were invited to participate in
the NCSP for CRC screening between January 1, 2004 and
December 31, 2007. Excluded from the analysis were 528
participants with missing screening results. The first participation
to the NCSP was defined as the first screening, regardless of
screening experience outside the NCSP. Any screening after the
first screening was defined as consequent screening. The final
study sample consisted of 1,809,139 participants and 2,193,093
FOBTs. The current study used the NCSP databases, which
include informed consent for the collection of their screening
results and health data, obtaining informed consent for this specific
study was waived as the NCSP database was so large; this study
was approved by the institutional review board of the National
Cancer Center, Korea.
Ascertainment of outcome
The final CRC diagnosis, tumor stage, and histopathological
information were ascertained through linkage with the Korea
National Cancer Incidence Database (KNCIDB) at the Korea
Central Cancer Registry (KCCR). The KNCIDB contains 95% of
newly diagnosed malignancies in Korea [15]. We used the CRC
diagnoses reported to the KNCIDB through December 2008,
allowing 12 months after the initial screening for the diagnostic
work-up to be completed and the results to be fully reported.
Anatomical subsites were defined based on the tenth version of
the International Statistical Classification of Diseases and Related
Health Problems (ICD-10) [16]. The proximal colon was defined
as the cecum (C18.0), appendix (C18.1), ascending colon (C18.2),
hepatic flexure (C18.3), transverse colon (C18.4), and splenic
flexure of the colon (C18.5); the distal colon was defined as the
descending colon (C18.6) and sigmoid colon (C18.7). The rectum
included the rectosigmoid colon (C19) and rectum (C20).
Overlapping lesions of the colon (C18.8) and colon not otherwise
specified (C18.9) were not included in the subsite analysis.
Statistical analysis
We calculated the following performance measures of the
FOBT examinations: positivity rates, CRC detection rates,
interval cancer rates, sensitivity, specificity, and positive predictive
values (PPVs) for detecting CRC. CRC detection rates were
calculated as the number of CRCs detected per 1,000 FOBT
examinations within a year from the time of a positive screening in
the NCSP. Screening-detected cancer was defined as a cancer
registered to the Korea Central Cancer Registry within one year
of positive FOBT. Interval cancer rates were calculated as the
number of CRCs diagnosed within 1 year of a negative screening
per 1,000 negative examination results. Interval cancer was
defined as a CRC cancer that was diagnosed outside a screening
program within a year from the time of a negative screening in the
NCSP. PPV (i.e., the probability of a cancer diagnosis within 1
year after a positive screening examination) was estimated as the
number of cancers diagnosed per 100 positive examination results.
Program sensitivity was defined as the probability of a positive
FOBT screening, given a finding of cancer within 1 year after a
screening [true positive / (true positive + false negative)]. Program
FOBT Validity in an Organized Screening Setting
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specificity was defined as the probability of a negative FOBT
screening, given no finding of cancer within 1 year after a
screening [true negative / (true negative + false positive)].
Performance measures were stratified by first (prevalence) and
subsequent (incidence) examinations. The first CRC screening
that a participant underwent was designated as the first round,
regardless of any previous CRC screening. Additional screenings
received by these participants were considered to be subsequent
rounds. The results from subsequent CRC screenings were
excluded for all participants with a final diagnosis of CRC or
other cancer that had been identified during the first round of
screening. SAS software (ver. 9.1; SAS Institute Inc., Cary, NC,
USA) was used for all statistical calculations.
Results
A total of 2,193,093 FOBTs were included in the analysis, of
which 1,809,139 were a first screening and 383,954 were
subsequent screenings (Table 1). A total of 225,755 FOBTs were
administered and the numbers increased every year with 777,999
FOBTs administered in 2007. Fifty-five percent of FOBTs were
administered to women. Use of qualitative FOBT kits increased
each year.
Overall, FOBT positivity was 7.28% (Table 2). For the first
screening round, the screening-detected cancer rate was 1.38 per
1,000 and interval cancer rate was 1.0 per 1,000. These rates were
1.22 and 1.03, respectively, for the subsequent round. Both
screening-detected and interval cancer rates were higher for older
age groups and for men. Use of the qualitative FOBT kit showed
higher rates for screening-detected cancer, whereas the quantita-
tive FOBT kit showed higher rates for interval cancer, although
the differences were not statistically significant. Screening detected
cancer rates were higher for both the first and subsequent rounds
between 2004 and 2007, whereas interval cancer rates were lower
between 2005 and 2007.
Overall, the sensitivity of the FOBT was 59.7% for the first
screening round and 56.1% for the subsequent round (Table 3).
Sensitivity was higher for younger age groups, men, use of the
qualitative kit, and more recent years. Sensitivity was highest for
distal colon cancer, followed by rectal cancer and proximal colon
cancer in the first screening round. However, for the subsequent
screening round, sensitivities for distal colon cancer and rectal
cancer were similar (Table 4).
Discussion
In the current study, the sensitivity of the FOBT for CRC was
higher for the first round compared with the subsequent round,
screening conducted in more recent years, among men, older age
groups, and for distal colon cancer. A decrease in FOBT sensitivity
in subsequent screening rounds was observed in an organized
screening in Israel. In that study, sensitivities for detecting a
cancer, adenoma, or polyp were 85.3% in the first round and
69.2% in the second round [17]. However, the sensitivity was
higher for the subsequent round (84%) than the first round
(57.3%) in an Italian study [12].
Immunochemical FOBT generally shows better sensitivity and
PPV compared with guaiac FOBT [18–23]. Therefore, NCSP
requires immunochemical FOBT as the primary screening
modality. The proportion of quantitative immunochemical FOBT
use within the NCSP compared with the qualitative immuno-
chemical FOBT increased gradually between 2004 and 2007.
Qualitative FOBT showed better sensitivity, whereas quantitative
FOBT showed better specificity and PPV. Although the NCSP did
not require reporting the commercial name of the FOBT used or
the cut-off point, we assumed that the qualitative FOBT set a
lower fecal Hb threshold than the quantitative FOBT [23,24]. In
addition, positivity rates of the FOBT in our study were relatively
high compared with other studies of average-risk populations,
where positivity rates range between 2.0% and 8.1% [20–22,25].
The positivity rates for the qualitative FOBT were three times
higher than those for the quantitative FOBT, and the transition to
widespread use of the quantitative FOBT would further lead to an
overall lower positivity rate in the future [26].
The sensitivity of the FOBT was higher for men than women,
especially for the first screening round in our study. This result is
consistent with the results from a Finnish randomized screening
program, which showed a sensitivity of 61.8% in men and 47.8%
in women [27], and with results from a population-based study in
Italy, where sensitivities were 78.4% for men and 66.6% for
women, although the differences were not statistically significant
[12]. High PPV and sensitivity among men and older age groups
were observed in a Dutch study [25]. The higher PPV and
sensitivity for CRC detection found in men compared with women
may be explained by the higher incidence rates of CRC and
colorectal adenoma in men. In the Korean population, the male-
to-female colorectal incidence rate ratios (IRR) were 1.29,1.57
between 1999 and 2009 [4]. High PPV and sensitivity among
older age groups may also be explained by age-specific incidence
patterns.
In our study, the sensitivity of the FOBT for detecting CRC was
highest for distal colon cancer and rectal cancer compared with
proximal colon cancer. Our result is partly consistent with the
Israeli study, in which the FOBT showed the highest sensitivity for
the left and sigmoid colon (87.9%) and similar sensitivity for the
Table 1. Characteristics of the screening participants (by each
screening for participants with multiple screenings) of the
National Cancer Screening Program, 2004-2007.
FOBT kits
Qualitative Quantitative NA
Screening round
First screening round 1,449,081 (83.2) 354,014 (79.8) 6,044 (85.0)
Subsequent screening round 293,544 (16.8) 89,340 (20.2) 1,070 (15.0)
Age (N, %)
50-59 848,957 (48.7) 216,961 (48.9) 3,239 (45.5)
60-69 648,127 (37.2) 168,510 (38.0) 2,695 (37.9)
70+ 245,541 (14.1) 57,883 (13.1) 1,180 (16.6)
Sex (N, %)
Men 783,623 (45.0) 193,329 (43.6) 3,087 (43.4)
Women 959,002 (55.0) 250,025 (56.4) 4,027 (56.6)
Insurance type (N, %)
MAP 216,441 (12.4) 48,776 (11.0) 2,007 (28.2)
NHI 1,526,184 (87.6) 394,578 (89.0) 5,107 (71.8)
Screening year
2004 193,636 (11.1) 29,525 (6.6) 2,594 (36.5)
2005 422,253 (24.2) 75,401 (17.0) 766 (10.8)
2006 568,091 (32.6) 121,367 (27.4) 1,461 (20.5)
2007 558,645 (32.1) 217,061 (49.0) 2,293 (32.2)
MAP, Medical Aid program; NHI, National Health Insurance
doi:10.1371/journal.pone.0079292.t001
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right and transverse colon (78.6%) and rectum (78.6%) [17]. In
contrast, sensitivities of the FOBT were not different by cancer
subsite in an Italian study (72.7% for colon vs. 75.8% for rectum)
[12]. The average FOBT Hb content has been shown to be higher
for those who possess a left-sided colon adenoma compared with
those who have a right-sided colon adenoma [13] or cancer [23].
However, the latter study showed high FOBT Hb content among
patients with an advanced adenoma in the proximal colon
compared with patients with an advanced adenoma in the distal
colon [23]. Reasons suggested for the high sensitivity of the FOBT
for distal colon cancer compared with proximal colon cancer are
as follows: 1) a higher proportion of pedunculated adenomas in the
left colon, which are more likely to have advanced histology, 2)
solid stool in the left-sided colon causes mechanistic irritation to
neoplasia and, thus, bleeding, and 3) hemoglobin, the molecular
target of the FOBT, which originates from right-sided neoplasia is
subjected to more degradation compared with hemoglobin
originating from left-sided neoplasia [14]. As a result of the
relatively low sensitivity of the FOBT for proximal colon cancer,
the proportion of proximal colon cancers increased among interval
cancers.
In the current study, the sensitivity of the FOBT for colorectal
cancer was 60% for the first round and 56% for the subsequent
round. The sensitivity of the FOBT test in the current study was
similar with the previous studies conducted in other countries.
According to the recent study, sensitivities for qualitative FOBT
tests were ranged from 30% to 73% [28]. The Spain study using
the OC-Light kit that specifically detects human haemogliblin with
sensitivity of 50 ng/ml buffer and popularly used in Korea,
showed sensitivity of 61% [29]. The large Japanese study of nearly
22,000 asymptomatic, average-risk patients who were given a
quantitative immunochemical FOBT, the sensitivity of FOBT for
detecting invasive cancer was 65.8% [30]. The results of meta-
analysis demonstrated the sensitivity of fecal immunochemical test
was 67% (95% CI: 61%–73%) [31]. Generally, it is difficult to
directly compare the results of different studies due to differences
in the target populations and different methods used in the
colorectal cancer screening programs. In addition, most previous
Table 3. Validity of FOBT for colorectal cancer.
First screening round Subsequent screening round
Sensitivity, %
(95% CI)
Specificity, %
(95% CI)
Positive predictive
value, % (95% CI)
Sensitivity, %
(95% CI)
Specificity, %
(95% CI)
Positive predictive
value, % (95% CI)
Overall 59.72 (58.21–61.21) 92.75 (92.71–92.78) 1.87 (1.80–1.94) 56.15 (52.71–59.54) 93.26 (93.18–93.34) 1.79 (1.63–1.96)
Age
50–59 61.79 (59.15–64.36) 93.09 (93.03–93.14) 1.33 (1.25–1.43) 58.10 (51.10–64.79) 93.78 (93.66–93.90) 1.22 (1.02–1.46)
60–69 59.74 (57.42–62.02) 92.56 (92.49–92.62) 2.15 (2.03–2.29) 57.92 (52.93–62.76) 93.07 (92.94–93.19) 2.00 (1.75–2.27)
70+ 56.87 (53.75–59.94) 91.99 (91.88–92.09) 2.85 (2.63–3.09) 51.12 (44.38–57.83) 92.39 (92.17–92.60) 2.48 (2.06–2.99)
Sex
Men 61.92 (60.03–63.79) 91.52 (91.46–91.58) 2.35 (2.24–2.47) 56.70 (52.53–60.77) 92.26 (92.13–92.38) 2.22 (1.99–2.47)
Women 56.05 (53.54–58.52) 93.70 (93.65–93.75) 1.35 (1.27–1.45) 54.96 (48.72–61.06) 94.20 (94.09–94.30) 1.24 (1.05–1.46)
FOBT kit
Qualitative 61.77 (60.09–63.43) 91.65 (91.60–91.70) 1.67 (1.60–1.74) 58.07 (54.15–61.90) 91.91 (91.81–92.01) 1.55 (1.40–1.72)
Quantitative 51.73 (48.29–55.15) 97.31 (97.26–97.36) 4.37 (3.98–4.79) 49.48 (42.23–56.75) 97.70 (97.59–97.79) 4.42 (3.61–5.40)
NA 53.33 (27.42–77.72) 88.12 (87.27–88.92) 1.10 (0.51–2.26) 100.00 (5.46–100.00) 92.24 (90.43–93.74) 1.19 (0.06–7.37)
Year of screening
2004 49.79 (45.25–54.34) 93.02 (92.91–93.12) 1.50 (1.32–1.71) NA NA NA
2005 58.44 (55.38–61.43) 93.24 (93.17–93.32) 1.91 (1.76–2.07) 44.93 (33.10–57.32) 93.10 (92.81–93.38) 1.43 (0.99–2.04)
2006 61.17 (58.45–63.81) 92.26 (92.19–92.32) 1.76 (1.64–1.88) 53.17 (46.82–59.44) 92.74 (92.59–92.89) 1.60 (1.34–1.89)
2007 62.90 (60.24–65.49) 92.72 (92.65–92.79) 2.10(1.97–2.25) 59.11 (54.72–63.36) 93.53 (93.43–93.62) 1.94 (1.73–2.17)
doi:10.1371/journal.pone.0079292.t003
Table 4. Validity of FOBT for colorectal cancer by anatomical location.
First screening round Subsequent screening round
Screening-detected,
n, (%)
Interval cancer
n, (%)
Sensitivity
% (95% CI)
Screening-detected,
n, (%)
Interval cancer
n, (%)
Sensitivity
% (95% CI)
Location
Proximal colon 450 (18.07) 354 (21.07) 55.97 (52.46–59.43) 74 (15.74) 76 (20.71) 49.33 (41.13–57.58)
Distal colon 816 (32.76) 423 (25.18) 65.86 (63.13–68.49) 131 (27.87) 96 (26.16) 57.71(50.99–64.17)
Rectum 1032 (41.43) 773 (46.01) 57.17 (54.85–59.47) 229 (48.72) 163 (44.41) 58.42 (53.35–63.32)
NA 193 (7.75) 130 (7.74) 59.75 (54.16–65.11) 36 (7.66) 32 (8.72) 56.15 (40.54–65.01)
doi:10.1371/journal.pone.0079292.t004
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studies included participants who underwent one-time FOBT and
colonoscopy screening in clinical research settings, whereas our
study was based on a population-based screening program.
Therefore, comparison by screening intervals or screening rounds
was not applicable. However, the sensitivity of FOBT test in the
current study was within the rages reported by other studies.
Although sensitivity of FOBT in the current study was similar
with others, the effort to increase accuracy of FOBT test is needed.
Specifically, definition of cutoff is critical issue immunochemical
FOBT tests and should be redefined for several of the tests to limit
false-positive rates in population-based screening.
Limitations of the current study include the lack of complete
information on colonoscopy after a positive FOBT. If FOBT-
positive participants received a follow-up colonoscopy outside of
the NCSP, the colonoscopy findings were not reported to the
NCSP. Therefore, we could not assess the actual proportion of
colonoscopy follow-up after an FOBT-positive screening. Low
follow-up rates may have lead to an underestimation of screening-
detected CRC rates. The follow-up rates among FOBT-positive
participants were 39,61% between 2004 and 2008 [32]. Lack of
colonoscopy follow-up may also have lead to contamination of
interval cancers detected during the subsequent round with missed
cancer after positive FOBT due to lack of follow-up colonoscopy
[33]. However, since the NSCP requires colonoscopy rather than
sigmoidoscopy as a follow-up modality, systemic under-detection
for proximal colon cancer should be minimized. In addition, due
to limitations in detailed clinical information on follow-up
colonoscopy findings, we could not use colorectal polyps as an
outcome for the calculated test validity. Including colorectal polyps
as an outcome would lead to better sensitivity for detecting
advanced neoplasms. CRC screening experience outside the
NSCP was not considered for assigning the first and the
subsequent screening round. This possible misclassification is
however expected to be non-differential between the first and the
subsequent screening rounds.
In conclusion, the FOBT showed reasonable validity in an
organized screening setting. Several factors, including screening
round, use of a quantitative kit, participant’s age and sex, and the
anatomical locations of colorectal cancer affected FOBT sensitivity
in the NCSP in Korea.
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